Clinical Trials Logo

Clinical Trial Summary

Introduction: Acute kidney injury (AKI) occurs up to 50% of patients admitted to intensive care unit. Plasma Endostatin, released from basement membrane of Bowman's capsule, rises early during AKI. Aim of Work: To investigate the role of the plasma endostatin in the outcome prediction (renal recovery, ICU stay, mortality) of acute kidney injury in patients with sepsis. Methods: a prospective, observational single center study on 40 patients with Sepsis at the Critical Care Department, Cairo University hospitals between March 2019 and November 2019. Serum plasma endostatin was measured at the day of admission & every 48hrs (3 samples). APACHE II, SOFA scores were calculated. Forced diuresis was used if indicated.


Clinical Trial Description

The study was conducted on 40 patients with sepsis who admitted in the Critical Care department of Cairo University. The sepsis is identified according to surviving sepsis campaign guidelines with use of SOFA score to establish the diagnosis. The patients divided into 2 groups the first group included 25 patients who developed AKI as defined by KDIGO guidelines and the other group included 15 patients as a control group. The Plasma Endostatin level is sampled in the first 24 hours of diagnosis of AKI, the estimation of plasma Endostatin level done by ELISA technique. The results were presented in form of: descriptive, analytical and comparative data between the groups of study. It was found that the patients with higher levels of plasma endostatin had a higher incidence of recovery from AKI and higher incidence of 28 days survival, while the patients with lower levels of plasma Endostatin below the determined Cut-off value have increased incidence of RRT . Also that the patients with higher levels of plasma Endostatin levels were less labile to mechanical ventilation and had a higher incidence of weaning of vasopressors in comparison of the other group of lower levels of plasma Endostatin. Plasma Endostatin levels have no difference between the AKI group and sepsis group which may need further investigations to determine its role in sepsis. so that, the plasma Endostatin can be used as a marker of recovery from AKI. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04633746
Study type Observational
Source Cairo University
Contact
Status Completed
Phase
Start date January 20, 2019
Completion date August 31, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05114057 - Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI N/A
Active, not recruiting NCT05507437 - Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury Phase 2
Terminated NCT04411472 - (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI Phase 3
Recruiting NCT05939245 - Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group N/A
Recruiting NCT06295393 - Renin Angiotensin Aldosterone System In Septic Kids
Recruiting NCT05996835 - Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI) Phase 2
Recruiting NCT05575024 - Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane
Completed NCT05060679 - Presepsin:Gelsolin Ratio in Sepsis-related Organ Dysfunction
Completed NCT04968262 - Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury
Not yet recruiting NCT05559086 - N/LP Ratio as Predictor of Mortality in Septic AKI Patients
Recruiting NCT05982340 - Endogenous Lithium Clearance in Acute Kidney Injury